#San Francisco #Australia #J.P. Morgan #Kazia Therapeutics #Paxalisib

Kazia Therapeutics to Present at J.P. Morgan Healthcare Conference

Kazia Therapeutics, a pioneering oncology company focused on innovative drug development, is poised to make a significant impact at the upcoming J.P. Morgan Healthcare Conference in San Francisco. Scheduled for next week, the event will highlight crucial interactions between Kazia's CEO, Dr. John Friend, and key institutional investors, analysts, and potential collaborators.

Dr. Friend shared exciting news about the company’s strategic position, stating, "We are entering JPM Week with strong strategic and clinical momentum." This follows Kazia's successful fundraising, which has fortified its financial standing and prepared it for immediate clinical endeavors. Notably, the company is set to release updates on its promising drug candidate, paxalisib, focusing on its application in treating triple-negative breast cancer (TNBC).

Anticipated Clinical and Translational Updates

As part of its progress, Kazia will provide a clinical update on its ongoing Phase 1b trial of paxalisib before the end of the month. This update is expected to delve deeper into the drug's efficacy against advanced TNBC. The information shared may encompass significant findings related to clinical responses and biomarker analyses, which could illuminate how paxalisib impacts the biology of metastatic diseases.

Importantly, previous data has shown that treatment with paxalisib correlates with rapid reductions in circulating tumor cells (CTCs) and CTC clusters, both of which are vital indicators of cancer metastasis and poor prognosis. Dr. Friend noted that in prior instances, temporary halts in paxalisib dosing were associated with increases in CTC clusters. However, reinitiating treatment led to reductions in these measures, spotlighting paxalisib's unique role compared to current immunotherapies.

The forthcoming data is expected to considerably enhance the understanding of paxalisib's effectiveness in the context of metastatic breast cancer, thus potentially refining Kazia's strategic approach for advancing its drug through various breast cancer subtypes.

New Initiatives on the Horizon

In addition to the updates on paxalisib, Kazia is eager to present the initial insights on its novel PD-L1 protein degrader program. This innovative approach aims to tackle the challenges associated with immune-based cancer therapies, particularly concerning biological complexity, resistance, and maintaining treatment durability.

Kazia's strategic vision aligns with evolving industry perspectives focused on differentiated mechanisms of action in oncology. This intention to leverage unique scientific advancements underscores the company's commitment to developing effective cancer therapies that address critical unmet medical needs.

About Kazia Therapeutics Limited

Based in Sydney, Australia, Kazia Therapeutics is an emerging leader in oncology therapeutics. The company's primary asset, paxalisib, is a brain-penetrant pan-PI3K/mTOR inhibitor currently under investigation for treating a range of brain cancers, including glioblastoma. Moreover, Kazia is exploring the use of paxalisib alongside checkpoint inhibitors and chemotherapy specifically for patients with advanced TNBC, marking its dedication to pushing boundaries in cancer care.

Kazia also advances a selective VEGFR3 inhibitor, EVT801, which is currently in Phase 1 clinical trials targeting advanced solid tumors. By focusing on potent clinical research and rapid asset development, Kazia aims to bring forth innovative solutions to the oncology market.

Forward Looking Statements

This announcement may contain forward-looking statements relating to Kazia Therapeutics' future plans and potential. The firm's strategic goals are subject to various risks and uncertainties, which could cause actual outcomes to differ from anticipated results. Investors are advised to consider the comprehensive risks outlined in Kazia's reports filed with the SEC, emphasizing that forward-looking statements are provided for guidance and should not be overly relied upon for future performance expectations.

For more information, interested parties may reach out to Kate Hill at Kazia Therapeutics.